Eton Pharmaceuticals develops proprietary formulations of approved molecules to create effective therapies for patients with rare diseases. The company focuses on rapid commercialization of these products, addressing the lack of treatment options for underserved populations.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare diseases often lack access to effective therapies due to the limited commercial viability of developing treatments for small populations. This results in a significant unmet need for specialized formulations and readily available medications tailored to these unique conditions.
Solution
Eton Pharmaceuticals focuses on acquiring and developing proprietary formulations of already-approved molecules to address the therapeutic gaps in rare disease treatment. By reformulating existing drugs, Eton aims to rapidly commercialize therapies that meet the specific needs of underserved patient populations. The company's business model centers on identifying and developing products with an established foundation, enabling efficient development and faster access to treatment options for patients with rare diseases.
Target Audience
Eton Pharmaceuticals primarily serves patients with rare diseases and the healthcare providers who treat them, offering specialized therapies where limited or no treatment options currently exist.
Features
- Focus on proprietary reformulations of approved molecules.
- Rapid commercialization strategy to quickly bring therapies to market.
- Diversified pipeline of product candidates targeting various rare diseases.
- Business model centered on products with existing clinical data and regulatory pathways.